Mensenkamp A R, Jong M C, van Goor H, van Luyn M J, Bloks V, Havinga R, Voshol P J, Hofker M H, van Dijk K W, Havekes L M, Kuipers F
Groningen Institute for Drug Studies, University Hospital Groningen, 9713 GZ Groningen.
J Biol Chem. 1999 Dec 10;274(50):35711-8. doi: 10.1074/jbc.274.50.35711.
ApoE-deficient mice on low fat diet show hepatic triglyceride accumulation and a reduced very low density lipoprotein (VLDL) triglyceride production rate. To establish the role of apoE in the regulation of hepatic VLDL production, the human APOE3 gene was introduced into apoE-deficient mice by cross-breeding with APOE3 transgenics (APOE3/apoe-/- mice) or by adenoviral transduction. APOE3 was expressed in the liver and, to a lesser extent, in brain, spleen, and lung of transgenic APOE3/apoe-/- mice similar to endogenous apoe. Plasma cholesterol levels in APOE/apoe-/- mice (3.4 +/- 0.5 mM) were reduced when compared with apoe-/- mice (12.6 +/- 1.4 mM) but still elevated when compared with wild type control values (1.9 +/- 0.1 mM). Hepatic triglyceride accumulation in apoE-deficient mice was completely reversed by introduction of the APOE3 transgene. The in vivo hepatic VLDL-triglyceride production rate was reduced to 36% of control values in apoE-deficient mice but normalized in APOE3/apoe-/- mice. Hepatic secretion of apoB was not affected in either of the strains. Secretion of (3)H-labeled triglycerides synthesized from [(3)H]glycerol by cultured hepatocytes from apoE-deficient mice was four times lower than by APOE3/apoe-/- or control hepatocytes. The average size of secreted VLDL particles produced by cultured apoE-deficient hepatocytes was significantly reduced when compared with those of APOE3/apoe-/- and wild type mice. Hepatic expression of human APOE3 cDNA via adenovirus-mediated gene transfer in apoE-deficient mice resulted in a reduction of plasma cholesterol depending on plasma apoE3 levels. The in vivo VLDL-triglyceride production rate in these mice was increased up to 500% compared with LacZ-injected controls and correlated with the amount of apoE3 per particle. These findings indicate a regulatory role of apoE in hepatic VLDL-triglyceride secretion, independent from its role in lipoprotein clearance.
低脂饮食的载脂蛋白E缺乏小鼠表现出肝脏甘油三酯积累以及极低密度脂蛋白(VLDL)甘油三酯生成率降低。为确定载脂蛋白E在肝脏VLDL生成调节中的作用,通过与APOE3转基因小鼠杂交(APOE3/apoe-/-小鼠)或腺病毒转导,将人类APOE3基因导入载脂蛋白E缺乏小鼠。APOE3在转基因APOE3/apoe-/-小鼠的肝脏中表达,在脑、脾和肺中的表达程度较低,类似于内源性载脂蛋白E。与载脂蛋白E缺乏小鼠(12.6±1.4 mM)相比,APOE/apoe-/-小鼠的血浆胆固醇水平(3.4±0.5 mM)降低,但与野生型对照值(1.9±0.1 mM)相比仍升高。通过导入APOE3转基因,载脂蛋白E缺乏小鼠肝脏中的甘油三酯积累完全逆转。载脂蛋白E缺乏小鼠体内肝脏VLDL-甘油三酯生成率降至对照值的36%,但在APOE3/apoe-/-小鼠中恢复正常。两种品系中载脂蛋白B的肝脏分泌均未受影响。载脂蛋白E缺乏小鼠培养肝细胞从[3H]甘油合成的(3)H标记甘油三酯的分泌量比APOE3/apoe-/-或对照肝细胞低四倍。与APOE3/apoe-/-和野生型小鼠相比,载脂蛋白E缺乏小鼠培养肝细胞分泌的VLDL颗粒平均大小显著减小。通过腺病毒介导的基因转移在载脂蛋白E缺乏小鼠中肝脏表达人类APOE3 cDNA,导致血浆胆固醇降低,这取决于血浆载脂蛋白E3水平。与注射LacZ的对照相比,这些小鼠体内VLDL-甘油三酯生成率提高高达500%,且与每个颗粒中的载脂蛋白E3量相关。这些发现表明载脂蛋白E在肝脏VLDL-甘油三酯分泌中具有调节作用,与其在脂蛋白清除中的作用无关。